HOME >> BIOLOGY >> NEWS
'Man's best friend' may be even better

ng-Plough Research Institute, Kenilworth, NJ. Their findings appear in the May 2003 edition of the Journal of Applied Physiology.

Methodology

Beagles, sensitized to ragweed allergen at birth, were subjected to inhalation of the ragweed extract into the lower respiratory tract inducing a systemic anaphylactic response that manifested in bronchoconstriction, alteration of a breathing pattern, increase in bronchial mucociliary clearance, and temporary cardiovascular depression. The researchers believed that, in these dogs, exclusive exposure of the upper respiratory tract to the same ragweed allergen would precipitate the development of allergic rhinitis that was responsive to treatment with a-adrenergic agonists.

To test this hypothesis, they evaluated the degree of nasal congestion induced by ragweed and histamine in cohorts of ragweed-sensitized, sham-sensitized, and nonsensitized dogs. Nasal congestion was assessed by the measurement of the resistance to conducting air, i.e., nasal airway resistance (RNA) and the relative cross-sectional areas and the volume of nasal passages.

Three series of experiments were conducted on subgroups selected from 14 adult beagle dogs of both sexes, weighing 9.514.5 kg. Five dogs were neonatally sensitized to ragweed, three were their sham-sensitized littermates, and six dogs were nonsensitized. Newborn dogs were sensitized with intraperitoneal injections containing ragweed extract in a saline mix and aluminum hydroxide within 24 hours of birth. Injections were repeated weekly for six weeks and biweekly until 16 weeks of age. In the sham-sensitized animals, only the aluminum hydroxide in saline was injected. Five-milliliter samples of venous blood were drawn from each dog beginning at four months of age and thereafter four times per year to measure serum ragweed-specific IgE levels.

These sensitization and sham sensitization procedures were conducted in November 1992 (two dogs), J
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
17-Jun-2003


Page: 1 2 3 4

Related biology news :

1. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
2. Microbes eat their way to better concrete
3. Computer database being developed at Temple will allow for better inventory of chemicals
4. New and better drugs for tuberculosis goal of UH professor
5. Ants protect plants better when jacked up on nectar
6. The blind really do hear better
7. Microarrays, key genome expression trackers, work better when probes are sequence-verified
8. Researchers develop better understanding of immune response to viral infection
9. Crack babies do better when placed with non-family caregivers
10. A better way to copy DNA
11. Gene profiles could improve acute leukemia diagnosis and lead to better treatments

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Man best friend may even better

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: